Functions of the MDM2 oncoprotein

Abstract. The p53 protein is activated in response to physiological stress resulting in either a G1 arrest of cells or apoptosis. As such, p53 must be tightly regulated, and the MDM2 oncoprotein plays a central role in that regulatory process. The transcription of the Mdm2 oncogene is induced by the p53 protein after DNA damage, and the MDM2 protein then binds to p53 and blocks its activities as a tumour suppressor and promotes its degradation. These two proteins thus form an autoregulatory feedback loop in which p53 positively regulates MDM2 levels and MDM2 negatively regulates p53 levels and activity. Immediately after ultraviolet (UV) irradiation MDM2 messenger RNA and protein levels fall in a p53-independent fashion, resulting in increased p53 levels. The p53 protein is then activated as a transcription factor by posttranslational modification permitting p53 to initiate its cell-cycle arrest or apoptotic (programmed cell death) functions. At later times, after the repair of DNA, MDM2 levels increase in a p53-dependent fashion. This induction of MDM2 results in the inhibition of p53 transcriptional activity and the degradation of p53 protein. MDM2-p53 complexes in the nucleus are transported to the cytoplasm via signals present in the MDM2 protein, where p53 is degraded in the proteasome. Thus MDM2 acts as a nuclear-cytoplasmic shuttle for the p53 protein. There are many levels at which this process is regulated, and as such there are many places for chemotherapeutic interventions. The amino-terminal domain of the MDM2 protein is all that is required to bind the p53 protein. The MDM2 protein has additional domains and therefore may have additional functions. Any of these MDM2 domains may contribute to MDM2's activities as an oncogene independent of its inhibition of the tumour suppressor functions of p53. Thus MDM2 itself could be a target for cancer therapeutic intervention.

[1]  M. Ladanyi,et al.  MDM2 gene amplification in metastatic osteosarcoma. , 1993, Cancer research.

[2]  A. Bernheim,et al.  MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). , 1996, Cytogenetics and cell genetics.

[3]  R. Tjian,et al.  Repression of p53-mediated transcription by MDM2: a dual mechanism. , 1997, Genes & development.

[4]  M. Oren,et al.  A functional p53-responsive intronic promoter is contained within the human mdm2 gene. , 1995, Nucleic acids research.

[5]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[6]  A. Levine,et al.  Nuclear Export Is Required for Degradation of Endogenous p53 by MDM2 and Human Papillomavirus E6 , 1998, Molecular and Cellular Biology.

[7]  A. Levine,et al.  Mapping of the p53 and mdm-2 interaction domains. , 1993, Molecular and cellular biology.

[8]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[9]  A. Levine,et al.  mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein , 1996, Molecular and cellular biology.

[10]  V. Reinke,et al.  The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo , 1997, Oncogene.

[11]  Y. Yoshihama,et al.  p53 and MDM2 expression in oral squamous cell carcinoma. , 1996, Oncology.

[12]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[13]  T. Kinoshita,et al.  The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. , 1994, Blood.

[14]  A. Levine,et al.  Molecular Abnormalities of mdm 2 and p 53 Genes in Adult Soft Tissue Sarcomas ' , 2022 .

[15]  A. Levine,et al.  Induced α Helix in the VP16 Activation Domain upon Binding to a Human TAF , 1997 .

[16]  A. Levine,et al.  The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro , 1997, Molecular and cellular biology.

[17]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[18]  A. Levine,et al.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.

[19]  S. Stass,et al.  The human MDM-2 oncogene is overexpressed in leukemias. , 1993, Blood.

[20]  M. Schwab,et al.  Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. , 1995, Oncogene.

[21]  P. Meltzer,et al.  p53 Mutation and MDM2 amplification in human soft tissue sarcomas. , 1993, Cancer research.

[22]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[23]  A. Levine,et al.  Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. , 1993, Oncogene.

[24]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[25]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.

[26]  A. Levine,et al.  Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis , 1997, Oncogene.

[27]  M. Raffeld,et al.  The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. , 1996, The American journal of pathology.

[28]  W. Sellers,et al.  Interaction between the retinoblastoma protein and the oncoprotein MDM2 , 1995, Nature.

[29]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[30]  G. Lozano,et al.  Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. , 1997, Genes & development.

[31]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[32]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[33]  V. P. Collins,et al.  Analysis of glioma cell lines for amplification and overexpression of MDM2 , 1994, Genes, chromosomes & cancer.

[34]  G. Lozano,et al.  The organization and expression of the mdm2 gene. , 1996, Genomics.

[35]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[36]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[37]  A. Levine,et al.  Differential Regulation of the p21/WAF-1 and mdm2 Genes after High-Dose UV Irradiation: p53-Dependent and p53-Independent Regulation of the mdm2 Gene , 1997, Molecular medicine.

[38]  G. Reifenberger,et al.  Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.

[39]  S. Tapscott,et al.  Amplification of MDM2 inhibits MyoD-mediated myogenesis , 1996, Molecular and cellular biology.

[40]  A. Levine,et al.  Human TAFII31 protein is a transcriptional coactivator of the p53 protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P S Meltzer,et al.  Isolation of genes amplified in human cancers by microdissection mediated cDNA capture. , 1996, Human molecular genetics.

[42]  H. Nguyen,et al.  Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[44]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[45]  A. Levine,et al.  The MDM2 Oncoprotein Binds Specifically to RNA through its RING Finger Domain , 1996, Molecular medicine.

[46]  P. Meltzer,et al.  Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. , 1996, Cancer research.

[47]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[48]  M. Ladanyi,et al.  p53 and MDM2 alterations in osteosarcomas , 1997, Cancer.

[49]  A. Levine,et al.  The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes , 1994, Molecular and cellular biology.

[50]  Jiandong Chen,et al.  Synergistic activation of p 53 by inhibition of MDM 2 expression and DNA damage , 1997 .

[51]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[52]  A. Levine,et al.  The mdm-2 gene is induced in response to UV light in a p53-dependent manner. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Yolande F M Ramos,et al.  Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. , 1997, Genomics.

[54]  C. Poremba,et al.  Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. , 1995, Oncology research.

[55]  P. Freemont,et al.  The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. , 1994, Trends in biochemical sciences.

[56]  G. Cooper,et al.  Identification of the MDM2 Oncoprotein as a Substrate for CPP32-like Apoptotic Proteases* , 1997, The Journal of Biological Chemistry.

[57]  M. Oren,et al.  Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. , 1994, Genes & development.

[58]  R. Tjian,et al.  p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. , 1995, Science.

[59]  A. Levine,et al.  Proteolytic Cleavage of the mdm2 Oncoprotein during Apoptosis* , 1997, The Journal of Biological Chemistry.

[60]  M. Oren,et al.  Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. , 1993, Oncogene.

[61]  B. Vogelstein,et al.  Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[62]  D. Beach,et al.  Cyclin G is a transcriptional target of the p53 tumor suppressor protein. , 1994, The EMBO journal.

[63]  A. Levine,et al.  Regulation of Transcription Functions of the p53 Tumor Suppressor by the mdm-2 Oncogene , 1995, Molecular medicine.

[64]  A. J. Levine The p53 tumor-suppressor gene. , 1992, The New England journal of medicine.

[65]  Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. , 1998, The EMBO journal.

[66]  U. Francke,et al.  Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line , 1987, Somatic cell and molecular genetics.

[67]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[68]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[69]  J. Landers,et al.  Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. , 1994, Oncogene.

[70]  D. George,et al.  Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.

[71]  A. Levine,et al.  A Genetic Approach to Mapping the p53 Binding Site in the MDM2 Protein , 1997, Molecular medicine.

[72]  J. Blaydes,et al.  Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2 , 1997, Oncogene.

[73]  C. Finlay,et al.  The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth , 1993, Molecular and cellular biology.

[74]  Jiandong Chen,et al.  Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[75]  M. Sheikh,et al.  The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. , 1993, Cancer research.